US Broker Ratings

Nuvation Bio Inc. (NUVB) Stock Analysis: Unveiling an 86% Potential Upside in the Biotech Arena

Nuvation Bio Inc. (NYSE: NUVB) has emerged as a compelling player in the biotechnology sector, drawing significant attention from investors due to its substantial growth potential. With a current market..

Spyre Therapeutics (SYRE) Investor Outlook: Unpacking a Potential 136% Upside

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is capturing the attention of investors with its promising developments in the biotechnology sector, specifically targeting inflammatory bowel disease (IBD). With a market cap of..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: A Biotech Gem with Nearly 98% Potential Upside

Investors on the hunt for opportunities in the volatile biotechnology sector should take a closer look at Taysha Gene Therapies, Inc. (NASDAQ: TSHA). With a market capitalization of $1.35 billion,..

AMN Healthcare Services Inc (AMN) Stock Analysis: Navigating Challenges with Strategic Workforce Solutions

AMN Healthcare Services Inc (NYSE: AMN) stands at the crossroads of healthcare and workforce management, offering a diverse array of staffing and technology-enabled solutions across the United States. As the..

RxSight, Inc. (RXST) Stock Analysis: Navigating Challenges and Potential Upside in the Medical Device Sector

RxSight, Inc. (NASDAQ: RXST), a pioneering company in the medical device sector, stands at the forefront of cataract surgery innovation with its light adjustable intraocular lenses (LAL). While the company..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: Eye-Catching 116% Potential Upside for Healthcare Investors

Niagen Bioscience, Inc. (NASDAQ: NAGE) is capturing the attention of investors in the healthcare sector, particularly those focused on biotechnology. With a current market capitalization of $591.77 million and a..

Pharvaris N.V. (PHVS) Stock Analysis: Exploring a Potential 61% Upside in the Biotech Sector

Pharvaris N.V. (PHVS), a Switzerland-based biopharmaceutical company, has piqued investor interest with its promising pipeline in the healthcare sector, specifically focusing on biotechnology. With a market capitalization of $1.48 billion,..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unpacking the 167% Potential Upside in Biotech

For investors seeking opportunities in the burgeoning field of biotechnology, Nurix Therapeutics, Inc. (NRIX) stands out with a compelling potential upside of 167.71%. As a clinical-stage biopharmaceutical company, Nurix is..

Simulations Plus, Inc. (SLP) Stock Analysis: Navigating a 33% Potential Upside in Health Information Services

Simulations Plus, Inc. (NASDAQ: SLP), a prominent player in the healthcare sector, specifically within health information services, presents a compelling case for investors seeking to capitalize on its potential upside...

Delcath Systems, Inc. (DCTH) Investor Outlook: Exploring a 126% Potential Upside in the Medical Device Space

Delcath Systems, Inc. (NASDAQ: DCTH) is drawing increasing attention in the medical device sector with a staggering potential upside of 126.40%. Specializing in interventional oncology, Delcath focuses on treating primary..

Beta Bionics, Inc. (BBNX) Stock Analysis: Strong Buy Ratings and 26.9% Upside Potential

Beta Bionics, Inc. (NASDAQ: BBNX), a pioneering medical device company headquartered in Irvine, California, is gaining notable traction in the healthcare sector with its innovative solutions for diabetes management. With..

Avadel Pharmaceuticals (AVDL) Stock Report: A 3% Upside Amid Robust Revenue Growth

Investors with an eye on the healthcare sector may find Avadel Pharmaceuticals plc (NASDAQ: AVDL) an intriguing opportunity. Based in Ireland, Avadel specializes in drug manufacturing within the specialty and..

CareDx, Inc. (CDNA) Stock Analysis: Exploring a Potential 48.53% Upside for Investors

For investors keen on the healthcare sector, CareDx, Inc. (NASDAQ: CDNA) presents a fascinating opportunity. Specializing in diagnostics and research, CareDx commands a market cap of $782.44 million and is..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 100% Upside Potential for Biotech Investors

Enliven Therapeutics, Inc. (NASDAQ: ELVN) stands out as a compelling opportunity within the healthcare sector, particularly for investors seeking exposure to the biotechnology industry. Headquartered in Boulder, Colorado, this clinical-stage..

CeriBell, Inc. (CBLL) Stock Analysis: Exploring a 119.70% Potential Upside in the Medical Device Sector

For investors with an affinity for the healthcare sector, particularly those eyeing innovation in medical devices, CeriBell, Inc. (CBLL) presents a compelling case. With a market capitalization of $474.43 million,..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a Potential 118.71% Upside in Biotechnology

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a promising player in the biotechnology sector, is catching the attention of investors with a substantial potential upside of 118.71%. Specializing in the development of..

Zymeworks Inc. (ZYME) Investor Outlook: Strong Buy Ratings and Significant Upside Potential

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company, is capturing investor attention with its compelling mix of cutting-edge therapeutic platforms and substantial growth potential. Operating within the healthcare sector and..

Immunome, Inc. (IMNM) Stock Analysis: A Biotech Contender with a 49% Potential Upside

Immunome, Inc. (NASDAQ: IMNM) is drawing investor attention with its promising potential upside of nearly 50%, as noted by analysts’ target price evaluations. As a clinical-stage biotechnology company, Immunome is..

Bicara Therapeutics Inc. (BCAX) Growth Potential: Analyst Ratings Signal 89.97% Upside

Bicara Therapeutics Inc. (NASDAQ: BCAX), a burgeoning player in the biotechnology sector, is capturing the attention of investors with a compelling growth narrative and an impressive analyst consensus pointing towards..

CureVac N.V. (CVAC) Stock Analysis: Navigating the mRNA Landscape with a 40.22% ROE

CureVac N.V. (NASDAQ: CVAC) is a biopharmaceutical company that has caught the attention of investors with its innovative approach to developing transformative medicines based on messenger RNA (mRNA) technology. Despite..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds